BNET Industries
- Private
- US
Dow Jones Description
Invitrogen is committed to being the leading provider of novel fluorescent reagents and detection solutions that advance scientific and biomedical research worldwide. Supplying superior Molecular Probes products and services, together with striving for customer and employee satisfaction, will be the driving forces of our organization.
Senior Vice President
Ben BulkleyPeer Companies
NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414
News & Analysis
Filter by
invitrogen corp. and life science - All News and Analysis
Invitrogen Wins Six Life Science Industry Awards
CARLSBAD, Calif. -- Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, today announced it was the winner in six categories at the annual Life Science Industry Awards.
Invitrogen to Present at the UBS 2007 Global Life Science Conference
CARLSBAD, Calif. -- Invitrogen Corporation (Nasdaq:IVGN), a provider of essential life science technologies for research, production and diagnostics, announced today that Greg Lucier, Chairman and Chief Executive Officer, will present at the UBS 2007 Global Life Science Conference being held at the Grand Hyatt, Park Avenue at Grand Central Terminal...
Invitrogen and FAST Create Premiere Life Science Search Capability
Invitrogen Website Enables Scientists to Solve a Fundamental Search Need by Providing Rich Scientific Data
Invitrogen Garners Six Life Science Industry Awards
CARLSBAD, Calif. -- Invitrogen Corporation (Nasdaq:IVGN), a provider of essential life science technologies for disease research and drug discovery, today announced it was recognized by the life sciences industry at The Scientists' annual Life Science Industry Awards, winning in six categories.
Invitrogen to Present at 2006 UBS Global Life Science Conference
CARLSBAD, Calif. -- Invitrogen Corporation (Nasdaq:IVGN) announced it will present at the 2006 UBS Global Life Science Conference on Tuesday, September 26, 2006 at 3:00 p.m. Eastern Time at the Grand Hyatt Hotel in New York City. To hear a live webcast of the presentation, visit the investor relations page...
Invitrogen Unveils New Innovations at American Association for Cancer Research Conference, Recognized by Peers at Life Science Industry Awards
WASHINGTON -- Industry Changing GIBCOR Functional Labels for Cell Culture Products and OmniaTM Kinase Assays That Measure Kinase Activity in Real Time Highlighted
Invitrogen and Wiley Partner to Offer Selected Current Protocols™ Online; Collaboration Provides Free Access to the Best Lab Methods Available Through New iProtocol™ Website
SAN FRANCISCO -- Invitrogen Corporation (Nasdaq:IVGN), a leading life sciences company with a broad portfolio of technologies to improve and accelerate biomedical research, drug discovery and commercial bioproduction, today announced the introduction of iProtocolTM, its latest technology and eScience contribution to the life sciences. Through a partnership with the global...
Invitrogen Launches Vector NTI® Advance™ 10; Release Includes Vector NTI® Open Access Policy and Vector NTI® User Community to Drive Life Science Standardization
CARLSBAD, Calif. -- Invitrogen Corporation (NASDAQ:IVGN), a leading life sciences company with a broad portfolio of technologies to improve and accelerate biomedical research, drug discovery and commercial bioproduction, today announced the release of its latest technology and eScience contribution to the life sciences, Vector NTI AdvanceTM 10. Centering on its...
Invitrogen to Present at UBS Global Life Sciences Conference
CARLSBAD, Calif. -- Invitrogen Corporation (Nasdaq:IVGN), announced today that Gregory T. Lucier, Invitrogen's Chairman and CEO, will present at the UBS Global Life Sciences Conference in New York City, New York today, September 27 at 11:00 a.m. Eastern Time. Mr. Lucier's presentation will be webcast and available for viewing live...
Invitrogen To Present at the UBS Global Life Sciences Conference
CARLSBAD, Calif. -- Invitrogen Corporation (Nasdaq:IVGN) announced that Gregory T. Lucier, Chairman and Chief Executive Officer, will be speaking at the UBS Global Life Sciences Conference on Monday, September 27, 2004 at 8:30 a.m. ET. The conference is being held at The Grand Hyatt in New York, N.Y.
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Ben Bulkley | Senior Vice President |
| David U'Prichard | Director |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Donald W Grimm | Board Member |
| Raymond V. Dittamore | Board of Directors |
| W. Ann Reynolds PhD | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Invitrogen Corporation | Senior Vice President | Current |
| UCSD-CONNECT | Director | Current |
| Organization | Position | Status |
|---|---|---|
| Care Capital, LLC | Venture Partner | Current |
| Red Abbey, LLC | Senior Advisor and Venture Partner | Current |
| University of Glasgow | Honorary Professor | Current |
| Red Abbey, LLC | Advisor | Current |
| Northwestern University | Associate Professor | Current |
| Glasgow University | Honorary Professor | Current |
| Genematrix, Inc. | Board Director | Current |
| Exsar Corporation | Board Director | Current |
| Guilford Pharmaceuticals, Inc. | Director | Current |
| Invitrogen Corporation | Director | Current |
| Cyclacel Limited | Board of Directors | Current |
| GlaxoSmithKline Plc | President | Former |
| SmithKline Beecham Corporation | President of Research and Development | Former |
| Druid Consulting | President | Former |
| Apax Partners Ltd. | Venture Partner | Former |
| Northwestern University School of Medicine | Associate Professor of Pharmacology and Neurobiology | Former |
| Biotechnology Industry Organization | member | Former |
| GlaxoSmithKline Plc | Chairman of Research and Development | Former |
| SmithKline Beecham Corporation | Chairman of R&D | Former |
| Biotechnology Industry Organization | Board Member | Former |
| University of Kansas | Ph.D. in Pharmacology | Former |
| University of Kansas | MS | Former |
| University of Glasgow | B.Sc. in Pharmacology | Former |
| Organization | Position | Status |
|---|---|---|
| Oligoperfect | Founder, Chairman and President, Strategic Design | Current |
| Pittsburgh Tissue Engineering Initiative, Inc | Founder, Chairman and President, Strategic Design | Current |
| Resgen Inc. | Founder, Chairman and President, Strategic Design | Current |
| Emiliem, Inc. | Founder, Chairman and President, Strategic Design | Current |
| Hamilton BioVentures | President | Current |
| Molecular Probes | Founder, Chairman and President, Strategic Design | Current |
| Biolayer Corporation Limited | Founder, Chairman and President, Strategic Design | Current |
| Strategic Design | President | Current |
| IDEXX Laboratories, Inc. | Founder, Chairman and President, Strategic Design | Current |
| Seqanswers | Founder, Chairman and President, Strategic Design | Current |
| Microseq | Founder, Chairman and President, Strategic Design | Current |
| Industry Ventures | Founder, Chairman and President, Strategic Design | Current |
| Olink | Founder, Chairman and President, Strategic Design | Current |
| Ionsource, LLC | Founder, Chairman and President, Strategic Design | Current |
| Bioreliance Corporation | Founder, Chairman and President | Current |
| Aegis Therapeutics, LLC | Executive Chairman | Current |
| Strategic Design | Chairman | Current |
| San Diego Regional Chamber of Commerce | Vice Chair | Current |
| Cellzdirect, Inc. | Board of Directors | Current |
| High Throughput Genomics, Inc. | Board of Directors | Current |
| Hamilton BioVentures | Director | Current |
| Intec Telecommunications | Board Member | Current |
| Invitrogen Corporation | Board Member | Current |
| University of Pittsburgh School of Pharmacy | Board Member | Current |
| Angstrom Pharmaceuticals, Inc. | Board of Directors | Current |
| Multiple Peptide Systems Inc | Board of Directors | Current |
| Scripps Clinic | Board Member | Current |
| Hybritech, Inc. | CEO | Former |
| Dura Pharmaceuticals, Inc. | Chief Executive Officer | Former |
| Biosource International, Inc. | Founder, Chairman and President, Strategic Design | Former |
| Hybritech, Inc. | President | Former |
| Copenhagen Capacity | Managing Director | Former |
| Hybritech, Inc. | Director of West Coast Pharmaceutical Sales | Former |
| Eli Lilly and Company | Director of Pharmaceutical Market Research | Former |
| Eli Lilly and Company | management positions | Former |
| U.S. Army | Officer | Former |
| Xcel Pharmaceuticals, Inc. | Former | |
| Verus Pharmaceuticals | Former | |
| Cadence Pharmaceuticals, Inc. | Former | |
| Hybritech, Inc. | Chairman | Former |
| Hybritech | Chairman | Former |
| Biovail Corporation | Chairman | Former |
| Pharmaceutical Market Research | Director | Former |
| Roundtable Inc. | Board of Directors | Former |
| Bioreliance Corporation | Director | Former |
| Somaxon Pharmaceuticals, Inc. | Board of Directors | Former |
| California Healthcare Institute, Inc. | Board of Directors | Former |
| University of Pittsburgh | M.B.A. | Former |
| Pittsburgh Tissue Engineering Initiative, Inc | M.B.A. | Former |
| Baldwin-Wallace College | Master's Degree In Business Administration | Former |
| Pittsburgh Tissue Engineering Initiative, Inc | B.S. In Pharmacy | Former |
| University of Pittsburgh | B.S. In Pharmacy | Former |
Raymond V. Dittamore has served as a Director of the Company since December 2002. Mr. Dittamore is a retired audit partner of Ernst & Young LLP, an international accounting firm. Mr. Dittamore retired in 2001 after 35 years of service with that firm, including 14 years as the managing partner of the firms San Diego office. Mr. Dittamore is also a director of Invitrogen Corporation, Gen-Probe Incorporated, and Digirad Corporation. Mr. Dittamore received a B.S. degree from San Diego State University.
| Organization | Position | Status |
|---|---|---|
| QUALCOMM Incorporated | Board of Directors | Current |
| Molecular Probes | Director | Current |
| Invitrogen Corporation | Board of Directors | Current |
| IDEXX Laboratories, Inc. | Board of Directors | Current |
| Biolayer Corporation Limited | Director | Current |
| Ionsource, LLC | Board of Directors | Current |
| Microseq | Board of Directors | Current |
| Pittsburgh Tissue Engineering Initiative, Inc | Board of Directors | Current |
| Industry Ventures | Board of Directors | Current |
| Gen-Probe Inc. | Board of Directors | Current |
| Applied Molecular Evolution, Inc. | Director | Current |
| Ernst & Young | partner | Former |
| Ernst & Young | collaborative editor | Former |
| Digirad Corporation | Board of Directors | Former |
| San Diego State University | B.S. | Former |
| QUALCOMM Incorporated | member | Former |
W. Ann Reynolds, 71, formerly President and Professor of Biology at The University of Alabama at Birmingham, located in Birmingham, Alabama, until 2002. Director since 2006; formerly a Director of OCD since 1993. A graduate of Kansas State Teachers College and the University of Iowa, where she earned a Ph.D. degree, Dr. Reynolds previously served as Chancellor of the City University of New York and as Chancellor of the California State University System. In prior years, she was Provost of the Ohio State University and Professor of Anatomy and Vice Chancellor for Research at the University of Illinois at the Medical Center. Dr. Reynolds is a director of Humana, Inc., Abbott Laboratories, Invitrogen Corporation, and the News-Gazette, Champaign, Illinois.
| Organization | Position | Status |
|---|---|---|
| News Gazette Inc. | Director | Current |
| Humana Inc. | Board of Directors | Current |
| Abbott Laboratories | Board of Directors | Current |
| Owens Corning | Board of Directors | Current |
| Industry Ventures | Board of Directors | Current |
| Business-Higher Education Forum | Member of The Board of The Champaign, Urbana News Gazette | Current |
| Olink | Board of Directors | Current |
| KMG America Corporation | Member of The Board of The Champaign, Urbana News Gazette | Current |
| IDEXX Laboratories, Inc. | Board of Directors | Current |
| Resgen Inc. | Board of Directors | Current |
| Maytag Corporation | Board of Directors | Current |
| Ionsource, LLC | Board of Directors | Current |
| Pittsburgh Tissue Engineering Initiative, Inc | Board of Directors | Current |
| Microseq | Board of Directors | Current |
| Abms Member | Board of Directors | Current |
| Invitrogen Corporation | Board of Directors | Current |
| The University of Alabama at Birmingham | President | Former |
| University of Illinois | Professor | Former |
| University of Illinois College of Medicine | Research Professor | Former |
| Emporia State University | M.S. | Former |
| Emporia State University | Bachelors Degree In Biology | Former |
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes


